NO20041850L - Fremgangsmate for dannelse av profenkrystaller - Google Patents
Fremgangsmate for dannelse av profenkrystallerInfo
- Publication number
- NO20041850L NO20041850L NO20041850A NO20041850A NO20041850L NO 20041850 L NO20041850 L NO 20041850L NO 20041850 A NO20041850 A NO 20041850A NO 20041850 A NO20041850 A NO 20041850A NO 20041850 L NO20041850 L NO 20041850L
- Authority
- NO
- Norway
- Prior art keywords
- prophene
- crystals
- forming
- prophene crystals
- forming prophene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10153934A DE10153934A1 (de) | 2001-11-06 | 2001-11-06 | Verfahren zur Kristallisation von Profenen |
PCT/EP2002/011999 WO2003039513A1 (fr) | 2001-11-06 | 2002-10-25 | Procede pour former des cristaux de profenes |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20041850L true NO20041850L (no) | 2004-05-05 |
Family
ID=7704443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20041850A NO20041850L (no) | 2001-11-06 | 2004-05-05 | Fremgangsmate for dannelse av profenkrystaller |
Country Status (14)
Country | Link |
---|---|
US (1) | US20050003000A1 (fr) |
EP (1) | EP1443906A1 (fr) |
JP (1) | JP2005512994A (fr) |
KR (1) | KR20050039732A (fr) |
CN (1) | CN1585630A (fr) |
BR (1) | BR0213878A (fr) |
CA (1) | CA2464756A1 (fr) |
DE (1) | DE10153934A1 (fr) |
HU (1) | HUP0402006A2 (fr) |
IL (1) | IL161406A0 (fr) |
MX (1) | MXPA04004236A (fr) |
NO (1) | NO20041850L (fr) |
RU (1) | RU2004117167A (fr) |
WO (1) | WO2003039513A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005037630A1 (de) | 2005-08-09 | 2007-02-15 | Glatt Gmbh | Verfahren zur Herstellung von Teilchen aus pharmazeutischen Substanzen, Teilchen aus pharmazeutischen Substanzen sowie deren Verwendung |
CZ297830B6 (cs) * | 2005-08-30 | 2007-04-11 | I.Q.A., A. S. | Zpusob výroby jemne krystalické smesi obsahující nesteroidní protizánetlivé lécivo, jemne krystalická smes pripravitelná tímto zpusobem a pevný farmaceutický prostredek tuto smes obsahující |
NZ574200A (en) | 2006-07-18 | 2011-02-25 | Horizon Therapeutics Inc | Methods and medicaments for administration of ibuprofen and famotidine |
WO2009008873A1 (fr) * | 2007-07-06 | 2009-01-15 | Basf Corporation | Composition de rétention gastrique sur la base d'un produit de réaction hydrosoluble en provenance d'un précurseur contenant un groupe vinyle |
ES2382618T3 (es) * | 2008-03-25 | 2012-06-11 | Formac Pharmaceuticals N.V. | Método de preparación para dispersiones sólidas |
JP5649453B2 (ja) * | 2008-12-04 | 2015-01-07 | 株式会社ネクスト21 | NSAIDs誘発性消化管粘膜障害軽減剤及びその製造方法 |
JPWO2011010456A1 (ja) * | 2009-07-24 | 2012-12-27 | 株式会社ネクスト21 | NSAIDs含有外用剤及び当該外用剤の製造方法 |
JP5750856B2 (ja) * | 2010-10-04 | 2015-07-22 | ライオン株式会社 | 固形医薬組成物及び医薬製剤 |
US9248139B2 (en) * | 2011-12-21 | 2016-02-02 | Bristol-Myers Squibb Company | Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients |
US10335371B2 (en) | 2015-02-17 | 2019-07-02 | Universiteit Gent | Solid pharmaceutical dosage form suitable for use as drinking water medication |
CN106397181B (zh) * | 2016-09-08 | 2019-01-01 | 山东理工大学 | 一种通过添加十二烷基硫酸钠自水溶液中制备长针状布洛芬晶体的方法 |
CN106518655B (zh) * | 2016-09-08 | 2019-01-04 | 山东理工大学 | 一种通过添加晶形控制剂自水溶液中制备片状布洛芬晶体的方法 |
CN110627629A (zh) * | 2019-10-15 | 2019-12-31 | 山东新华制药股份有限公司 | 一种多级连续反应结晶生产布洛芬的方法 |
JP2023084097A (ja) * | 2021-12-06 | 2023-06-16 | 花王株式会社 | 芳香族ヒドロキシカルボン酸結晶の製造方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4476248A (en) * | 1983-02-28 | 1984-10-09 | The Upjohn Company | Crystallization of ibuprofen |
US5141961A (en) * | 1991-06-27 | 1992-08-25 | Richrdson-Vicks Inc. | Process for solubilizing difficulty soluble pharmaceutical actives |
GB9119052D0 (en) * | 1991-09-06 | 1991-10-23 | Boots Co Plc | Pharmaceutical compositions |
JP3390477B2 (ja) * | 1993-01-25 | 2003-03-24 | 生化学工業株式会社 | 薬剤組成物及びその製造法 |
US5718919A (en) * | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
-
2001
- 2001-11-06 DE DE10153934A patent/DE10153934A1/de not_active Withdrawn
-
2002
- 2002-10-25 KR KR1020047006760A patent/KR20050039732A/ko not_active Application Discontinuation
- 2002-10-25 HU HU0402006A patent/HUP0402006A2/hu unknown
- 2002-10-25 RU RU2004117167/15A patent/RU2004117167A/ru not_active Application Discontinuation
- 2002-10-25 CN CNA02822213XA patent/CN1585630A/zh active Pending
- 2002-10-25 IL IL16140602A patent/IL161406A0/xx unknown
- 2002-10-25 EP EP02779512A patent/EP1443906A1/fr not_active Withdrawn
- 2002-10-25 BR BR0213878-6A patent/BR0213878A/pt not_active IP Right Cessation
- 2002-10-25 JP JP2003541804A patent/JP2005512994A/ja active Pending
- 2002-10-25 CA CA002464756A patent/CA2464756A1/fr not_active Abandoned
- 2002-10-25 US US10/494,764 patent/US20050003000A1/en not_active Abandoned
- 2002-10-25 WO PCT/EP2002/011999 patent/WO2003039513A1/fr not_active Application Discontinuation
- 2002-10-25 MX MXPA04004236A patent/MXPA04004236A/es unknown
-
2004
- 2004-05-05 NO NO20041850A patent/NO20041850L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2464756A1 (fr) | 2003-05-15 |
HUP0402006A2 (hu) | 2005-01-28 |
KR20050039732A (ko) | 2005-04-29 |
RU2004117167A (ru) | 2005-04-10 |
BR0213878A (pt) | 2004-08-31 |
MXPA04004236A (es) | 2004-07-08 |
US20050003000A1 (en) | 2005-01-06 |
WO2003039513A1 (fr) | 2003-05-15 |
EP1443906A1 (fr) | 2004-08-11 |
IL161406A0 (en) | 2004-09-27 |
CN1585630A (zh) | 2005-02-23 |
JP2005512994A (ja) | 2005-05-12 |
DE10153934A1 (de) | 2003-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20034969D0 (no) | Fremgangsmåte for fremstilling av olefiner | |
DK1293507T3 (da) | Fremgangsmåde til fremstilling af krystaller | |
NO20042680L (no) | Fremgangsmater for fremstilling av O-demetylvenflaxine | |
NO20033902D0 (no) | Fremgangsmåte for fremstilling av mellomdestillater | |
DE60211785D1 (de) | Bilderzeugungsverfahren | |
NO20030012L (no) | Fremgangsmåte for fremstilling av substituerte oktanoylamider | |
NO20052568D0 (no) | Fremgangsmate for fremstilling av makrolidforbindelse | |
NO20033887D0 (no) | Fremgangsmåte for fremstilling av stöpestykker | |
NO20040027L (no) | Fremgangsmate for fremstillingen av escitalopram | |
DE60235767D1 (de) | Sublimationsmuster-giessverfahren | |
NO20030163D0 (no) | Fremgangsmåte for fremstilling av olefiner | |
NO20040278L (no) | Fremgangsmate for fremstilling av perindopril | |
NO20041850L (no) | Fremgangsmate for dannelse av profenkrystaller | |
NO20041182L (no) | Fremgangsmate for fremstilling av silisium | |
NO20044814L (no) | Fremgangsmate for fremstilling av combretastaniner | |
DE60233109D1 (de) | Radidentifikator- ortungsverfahren | |
DE60130137D1 (de) | Kristallisationsverfahren | |
NO20041224L (no) | Fremgangsmate for fremstilling av hydrokarboner | |
NO20035586D0 (no) | Fremgangsmåte for fremstilling av cykloheksanol-derivater | |
NO20001134D0 (no) | FremgangsmÕte for fremstilling av VCM | |
DE60204089D1 (de) | Bilderzeugungsverfahren | |
NO20023087D0 (no) | Fremgangsmåte for fremstilling av kvartsdigler | |
FI20010472A0 (fi) | Menetelmä alfa-pineenin hydraamiseksi | |
NO20030515D0 (no) | Fremgangsmåte for fremstilling av dinapsolin | |
NO20014077L (no) | Fremgangsmåte for krystallisering av N-(4-trifluormetylfenyl)- 5-metyl-isoksazol-4-karboksamid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |